• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket

    3/20/24 8:20:39 AM ET
    $AQST
    $BCAN
    $CERO
    $CGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $AQST alert in real time by email

    Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results.

    The company reported fiscal year 2023 losses of 96 cents per share, compared to losses of $3.78 per share from the prior year. Taysha reported it had $143.9 million in cash and cash equivalents on Dec. 31, 2023.

    The company also provided clinical updates including the completed dosing in cohort one of its REVEAL Phase 1/2 adolescent and adult trial and the expansion of the ongoing trial in Canada into the U.S. and initiated site activation.

    Taysha Gene Therapies shares jumped 27.1% to $2.86 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • ETAO International Co., Ltd. (NASDAQ:ETAO) shares rose 200.4% to $0.4296 in pre-market trading. The company announced a reverse stock split.
    • Oblong, Inc. (NASDAQ:OBLG) rose 48.2% to $0.20 in pre-market trading after the company reported financial results for fourth quarter 2023 and issued a business update.
    • BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) climbed 44% to $0.0288 in pre-market trading after falling 15% on Tuesday. Aegis Capital acted as Sole bookrunner on a $7.0 million underwritten public offering for BYND Cannasoft Enterprises Inc.
    • Mangoceuticals, Inc. (NASDAQ:MGRX) shares rose 40.5% to $0.2698 in pre-market trading after gaining around 4% on Tuesday.
    • EZFill Holdings Inc. (NASDAQ:EZFL) gained 18% to $1.90 in pre-market trading after falling 9% on Tuesday.
    • SCWorx Corp. (NASDAQ:WORX) rose 16.9% to $3.32 in pre-market trading after surging around 54% on Tuesday.
    • BitFuFu Inc. (NASDAQ:FUFU) shares gained 11.7% to $6.03 in pre-market trading after gaining 32% on Tuesday.
    • Canopy Growth Corporation (NASDAQ:CGC) gained 14.4% to $4.38 in pre-market trading. VP Kamala Harris recently urged the DEA to reschedule marijuana.
    • Getty Images Holdings, Inc. (NYSE:GETY) shares rose 14% to $5.36 in pre-market trading. Getty Images recently reported better-than-expected fourth-quarter revenue results and issued FY24 revenue guidance.

    Losers

    • Ontrak, Inc. (NASDAQ:OTRK) dipped 20.5% to $0.35 in pre-market trading after jumping over 131% on Tuesday.
    • Momentus Inc. (NASDAQ:MNTS) fell 19.1% to $0.4803 pre-market trading, reversing after spiking 17% on Tuesday following a US patent grant.
    • Aquestive Therapeutics, Inc. (NASDAQ:AQST) fell 14.8% to $4.55 in pre-market trading. Aquestive Therapeutics priced its $75 million underwritten public offering of 16,666,667 common shares at $4.50 per share.
    • Verb Technology Company, Inc. (NASDAQ:VERB) fell 14.2% to $0.3309 pre-market trading after surging 7% on Tuesday. The company on Friday announced its Market.live launched Facebook and Instagram social shopping technology integration. Also, the company announced it added 100 more retail brands to its livestream social shopping platform.
    • Harrow, Inc. (NASDAQ:HROW) fell 14.6% to $9.09 in pre-market trading after posting weaker-than-expected fourth-quarter results.
    • NuScale Power Corporation (NYSE:SMR) shares tumbled 6.8% to $6.13 in pre-market trading. NuScale Power shares dipped around 35% on Tuesday after Wells Fargo downgraded the stock from Equal-Weight to Underweight and lowered its price target from $7.50 to $4.50.
    • CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) declined 6.4% to $2.25 in pre-market trading after surging 14% on Tuesday.
    • Clearmind Medicine Inc. (NASDAQ:CMND) shares fell 6.2% to $1.21 in pre-market trading. On Tuesday, Clearmind Medicine announced that it has been granted divisional patent approval by the China National Intellectual Property Administration.
    • MaxCyte, Inc. (NASDAQ:MXCT) shares tumbled 5.8% to $4.20 after gaining 7% on Tuesday. MaxCyte, last week, reported better-than-expected fourth-quarter financial results and issued FY24 guidance.
    • Society Pass Incorporated (NASDAQ:SOPA) shares fell 5% to $0.1456 in pre-market trading.

     

    Now Read This: Micron, Signet Jewelers And 3 Stocks To Watch Heading Into Wednesday

    Get the next $AQST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AQST
    $BCAN
    $CERO
    $CGC

    CompanyDatePrice TargetRatingAnalyst
    Canopy Growth Corporation
    $CGC
    3/27/2026Buy
    Canaccord Genuity
    NuScale Power Corporation
    $SMR
    2/27/2026$21.00Market Perform → Outperform
    Northland Capital
    NuScale Power Corporation
    $SMR
    2/11/2026Buy → Hold
    TD Cowen
    NuScale Power Corporation
    $SMR
    1/9/2026$28.00Underperform → Neutral
    BofA Securities
    Canopy Growth Corporation
    $CGC
    11/10/2025Sell → Hold
    The Benchmark Company
    NuScale Power Corporation
    $SMR
    10/21/2025Neutral → Underperform
    BNP Paribas Exane
    Taysha Gene Therapies Inc.
    $TSHA
    10/21/2025$13.00Strong Buy
    Raymond James
    NuScale Power Corporation
    $SMR
    10/21/2025$55.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AQST
    $BCAN
    $CERO
    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Canopy Growth

    Canaccord Genuity initiated coverage of Canopy Growth with a rating of Buy

    3/27/26 8:46:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    NuScale Power upgraded by Northland Capital with a new price target

    Northland Capital upgraded NuScale Power from Market Perform to Outperform and set a new price target of $21.00

    2/27/26 8:22:27 AM ET
    $SMR
    Metal Fabrications
    Industrials

    NuScale Power downgraded by TD Cowen

    TD Cowen downgraded NuScale Power from Buy to Hold

    2/11/26 7:50:27 AM ET
    $SMR
    Metal Fabrications
    Industrials

    $AQST
    $BCAN
    $CERO
    $CGC
    SEC Filings

    View All

    Getty Images Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - Getty Images Holdings, Inc. (0001898496) (Filer)

    4/3/26 4:54:09 PM ET
    $GETY
    Real Estate

    SEC Form S-8 filed by Momentus Inc.

    S-8 - Momentus Inc. (0001781162) (Filer)

    4/1/26 5:18:55 PM ET
    $MNTS
    Military/Government/Technical
    Industrials

    SEC Form NT 10-K filed by CERo Therapeutics Holdings Inc.

    NT 10-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

    4/1/26 4:10:19 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AQST
    $BCAN
    $CERO
    $CGC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    $BCAN
    $CERO
    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the Company's common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies,

    4/3/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 375,000 shares of MaxCyte's common stock and a service-based restricted stock unit ("RSU") award with respect to 187,500 shares of MaxCyte's common stock to Parmeet Ahuja in connection with his appointment as Chief Financial Officer of MaxCyte. The awards were granted unde

    3/31/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Mission Update on Momentus Vigoride 7 Orbital Service Vehicle

    Launched on March 30 on SpaceX Transporter‑16 Mission Carrying 10 Payloads Momentus Inc. (NASDAQ:MNTS) ("Momentus" or the "Company"), a U.S. commercial space company specializing in satellite technology, space transportation, and in‑orbit services, today announced the successful deployment and early commissioning of its Vigoride 7 Orbital Service Vehicle following launch aboard SpaceX's Transporter‑16 mission. Vigoride 7 represents a significant operational milestone for the Company as it begins a series of in space operations designed to test, validate and showcase a suite of next‑generation capabilities. Over the coming months, the spacecraft is expected to host and operate 10 governm

    3/31/26 8:00:00 AM ET
    $MNTS
    Military/Government/Technical
    Industrials

    $AQST
    $BCAN
    $CERO
    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Boeckmann Alan L

    4 - NUSCALE POWER Corp (0001822966) (Issuer)

    4/2/26 5:05:45 PM ET
    $SMR
    Metal Fabrications
    Industrials

    SEC Form 4 filed by Kresa Kent

    4 - NUSCALE POWER Corp (0001822966) (Issuer)

    4/2/26 5:04:08 PM ET
    $SMR
    Metal Fabrications
    Industrials

    SEC Form 4 filed by Leyden Jennifer

    4 - Getty Images Holdings, Inc. (0001898496) (Issuer)

    4/2/26 4:30:21 PM ET
    $GETY
    Real Estate

    $AQST
    $BCAN
    $CERO
    $CGC
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy Growth Announces Storz & Bickel Executive Transition

    David Männer appointed Managing Director Jürgen Bickel, who co-founded and built Storz & Bickel into a global premium vaporization technology leader, passes the torch following 25 years of transformational leadership Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced the appointment of David Männer as Managing Director of Storz & Bickel, a subsidiary of Canopy Growth, effective April 1, 2026. Mr. Männer succeeds Jürgen Bickel, Storz & Bickel's Co-founder, who has decided to transition out of his role. Founded in 2001, Storz & Bickel has grown into a global leader in vaporization technology. Today, it sets the standard for innovation, p

    3/27/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

    ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. "Parmeet is an exceptionally talented finance leader whose experience and expertise position him well to strengthen MaxCyte's financial operations," said Maher Masoud, Chief Executive Officer. "His deep background in

    3/23/26 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

    Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr

    3/20/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AQST
    $BCAN
    $CERO
    $CGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Holst Peter bought $9,500 worth of shares (5,000 units at $1.90), increasing direct ownership by 47% to 15,544 units (SEC Form 4)

    4 - Oblong, Inc. (0000746210) (Issuer)

    11/19/25 3:15:50 PM ET
    $OBLG
    Computer Software: Programming Data Processing
    Technology

    President and CEO Holst Peter bought $18,400 worth of shares (10,000 units at $1.84), increasing direct ownership by 1,838% to 10,544 units (SEC Form 4)

    4 - Oblong, Inc. (0000746210) (Issuer)

    11/17/25 1:12:26 PM ET
    $OBLG
    Computer Software: Programming Data Processing
    Technology

    Director Schechter Jonathan bought $19,100 worth of shares (10,000 units at $1.91), increasing direct ownership by 67% to 25,000 units (SEC Form 4)

    4 - Oblong, Inc. (0000746210) (Issuer)

    11/17/25 1:11:43 PM ET
    $OBLG
    Computer Software: Programming Data Processing
    Technology

    $AQST
    $BCAN
    $CERO
    $CGC
    Financials

    Live finance-specific insights

    View All

    MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

    Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md., March 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform

    3/24/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    BitFuFu Announces Unaudited 2025 Full-Year Financial Results

    SINGAPORE, March 20, 2026 (GLOBE NEWSWIRE) -- BitFuFu Inc. ("BitFuFu" or the "Company") (NASDAQ:FUFU), a world-leading Bitcoin miner and mining services innovator, today announced its unaudited financial results for the full year ended December 31, 2025. Full Year 2025 Financial Highlights Total revenue was $475.8 million in 2025, representing an increase of 2.7% from $463.3 million in 2024. The year-over-year increase was driven by higher revenue from Cloud Mining Solutions, Mining Equipment Sales, and Other, partially offset by a decline in revenue from Self-Mining Operations.   For the Year Ended December 31,   2025 2024Business Segment ($ in millions) Revenue % ofRevenue Revenue % of

    3/20/26 6:00:00 AM ET
    $FUFU
    Finance: Consumer Services
    Finance

    Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

    Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026 Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutoff; longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026 Reached written alignment with FDA on proposed PPQ

    3/19/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AQST
    $BCAN
    $CERO
    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

    SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    12/13/24 7:18:17 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary